Canavan, Mary Floudas, Achilleas Veale, Douglas J. Fearon, Ursula
Published in
BMC Rheumatology
The activation of antigen specific T cells during an immune response is a tightly regulated process at the level of both costimulatory and coinhibitory receptors. One such coinhibitory receptor or checkpoint inhibitor which has received much attention in the field of oncology is the programmed cell death protein 1 (PD-1). Blockade of PD-1 or its li...
Bendib, Inès Beldi-Ferchiou, Asma Schlemmer, Frédéric Surenaud, Mathieu Maitre, Bernard Plonquet, Anne Carteaux, Guillaume Razazi, Keyvan Godot, Veronique Hüe, Sophie
...
Published in
Critical Care
BackgroundBiomarkers of disease severity might help individualizing the management of patients with the acute respiratory distress syndrome (ARDS). Whether the alveolar compartmentalization of biomarkers has a clinical significance in patients with pneumonia-related ARDS is unknown. This study aimed at assessing the interrelation of ARDS/sepsis bio...
Yi, Ming Niu, Mengke Xu, Linping Luo, Suxia Wu, Kongming
Published in
Journal of Hematology & Oncology
Programmed death-ligand 1 (PD-L1) on cancer cells engages with programmed cell death-1 (PD-1) on immune cells, contributing to cancer immune escape. For multiple cancer types, the PD-1/PD-L1 axis is the major speed-limiting step of the anti-cancer immune response. In this context, blocking PD-1/PD-L1 could restore T cells from exhausted status and ...
Costa, Federica Marchica, Valentina Storti, Paola Malavasi, Fabio Giuliani, Nicola
Published in
Cancers
The emerging role of the PD-1/PD-L1 axis in MM immune-microenvironment has been highlighted by several studies. However, discordant data have been reported on PD-1/PD-L1 distribution within the bone marrow (BM) microenvironment of patients with monoclonal gammopathies. In addition, the efficacy of PD-1/PD-L1 blockade as a therapeutic strategy to re...
Breakstone, Rimini
Published in
Translational Gastroenterology and Hepatology
Immune checkpoint blockade (ICB) has changed the landscape of cancer therapy in multiple tumor types since the first agent, Ipilimumab, was first FDA approved for the treatment of metastatic melanoma in 2011. Its role in GI Cancers, particularly in colon cancers, has not been as robust as in other tumor types but select patients with DNA mismatch r...
Wu, Lei Quan, Wen Yue, Guojun Luo, Qiong Peng, Dongxu Pan, Ying Zhang, Guihai
Published in
BMC Cancer
BackgroundAutophagy is a highly conserved homeostatic process in the human body that is responsible for the elimination of aggregated proteins and damaged organelles. Several autophagy-related genes (ARGs) contribute to the process of tumorigenesis and metastasis of prostate cancer (PCa). Also, miRNAs have been proven to modulate autophagy by targe...
Lopez-Beltran, Antonio Cimadamore, Alessia Blanca, Ana Massari, Francesco Vau, Nuno Scarpelli, Marina Cheng, Liang Montironi, Rodolfo
Published in
Cancers
Simple Summary In this review, we examined relevant clinical trial results with immune checkpoint inhibitors in patients with metastatic urothelial cancer. We also focused on the potential of immunotherapy in the adjuvant and neoadjuvant setting or as part of drug combinations. Finally, we briefly review the current landscape of biomarkers of respo...
Tambaro, Rosa Napoli, Marilena Di Pisano, Carmela Cecere, Sabrina Chiara Attademo, Laura Rossetti, Sabrina Feroce, Florinda Setola, Sergio Califano, Daniela Russo, Daniela
...
Published in
Immunotherapy
Monoclonal antibodies targeting the checkpoint inhibitors (CPIs), programmed cell death protein-1 or programmed cell death ligand-1, are changing the landscape of urothelial carcinoma therapeutics. Overall, clinical studies in metastatic or advanced urothelial cancer showed that CPIs provided a slight improvement in survival and a relevant advantag...
Dutta, Indrani Dieters-Castator, Dylan Papatzimas, James W Medina, Anais Schueler, Julia Derksen, Darren J Lajoie, Gilles Postovit, Lynne-Marie Siegers, Gabrielle M
Published in
Cancer letters
Gamma delta T cells (γδTc) have tremendous anti-tumoral activity, thus γδTc immunotherapy is currently under development for various malignancies. We targeted breast cancer stem-like cells (BCSC), a rare cell population responsible for patient mortality. BCSC were mostly susceptible to γδTc immunotherapy, yet some escaped. The BCSC secretome render...
Hsu, Haoting Boudova, Sarah Mvula, Godfrey Divala, Titus H Rach, David Mungwira, Randy G Boldrin, Francesca Degiacomi, Giulia Manganelli, Riccardo Laufer, Miriam K
...
Published in
Cellular immunology
Human Vγ9Vδ2 T cells respond to several diverse pathogens by sensing microbial cholesterol intermediates. Unlike CD4 T cells, they are poised for rapid Th1-like responses even before birth, which allows them to play a key role in the first line of defense against pathogens in early life. However, their regulation and functional maturation during in...